Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients.
Morphoproteomics combines the disciplines of histopathology, molecular biology and protein chemistry to paint a portrait of the protein circuitry in diseased cells for the purpose of uncovering molecular targets amenable to specific intervention, thereby customizing therapy for individual patients. This review considers the clinical application of morphoproteomics in malignant cells in the context of currently available pharmaceutical agents and discusses opportunities for combinatorial approaches that involve one or more small molecule inhibitors and single-agent chemotherapy with relatively low toxicity profiles. Future directions that involve focusing on points of convergence in signal transduction pathways and which integrate morphoproteomic with genomic and pharmacoproteomic and protein-function microarray data are offered.
Geisinger Medical Center, Danville, PA 17822-0131, USA. rebrown@geisinger.edu
Robert E
RE
Brown
D023281:Genomics; D006801:Humans; D046228:Microarray Analysis / Q000379:methods*; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D040901:Proteomics
D009363:Neoplasm Proteins